User:MaryGaulke/sandbox/Beigene requests

Hi, I'm working as a COI editor for BeiGene again, requesting just a few more edits to this article:


 * In the lead, update
 * BeiGene, Ltd. is a China-based drug developer.
 * to
 * BeiGene, Ltd. is a drug developer headquartered in Cambridge, Massachusetts, with major offices in Beijing and Basel.
 * Swapping in a more recent and accurate source.


 * In the lead, update
 * BeiGene has a large presence in Chinese market.
 * to
 * BeiGene sells its products globally, with large presences in China, Europe and the U.S.


 * Move the first paragraph of "Research and development" ("In addition to clinical research,...late-stage trials.") to follow the second paragraph of "History". I believe this makes more sense there since it's not focused on the company's current business model.
 * Move
 * In September 2021, the U.S. Food and Drug Administration (FDA) accepted a biologics license application for tislelizumab to treat unresectable, recurrent locally advanced or metastatic esophageal squamous cell carcinoma that has previously been treated with systemic therapy.
 * from the end of the second paragraph of "Research and development" to the start of the fourth paragraph (before "As of 2023...") in order to put information in chronological order.


 * Add to end of third paragraph of "Research and development" (after "...an anti-CD20 regimen. "):
 * The FDA approved zanubrutinib plus obinutuzumab for the treatment of relapsed/refractory follicular lymphoma in March 2024.


 * In "History", update
 * The company initially primarily operated in China.
 * to
 * The company initially had a presence in both the U.S. (Philadelphia) and China (Beijing).


 * Move
 * In March 2024, tislelizumab (Tevimbra) received FDA approval for the treatment of advanced or metastic esophageal squamous cell carcinoma after prior chemotherapy. This FDA approval marked BeiGene's second for an internally developed medicine.
 * from the "History" section to the end of the second paragraph of "Research and development" (the one focused on tislelizumab). I also suggest updating to an external source and correcting the spelling of "metastatic", like so:
 * In March 2024, tislelizumab received FDA approval for the treatment of advanced or metastastic esophageal squamous cell carcinoma after prior chemotherapy. This FDA approval marked BeiGene's second for an internally developed medicine.


 * Add to end of penultimate paragraph of "History":
 * BeiGene and the non-profit BeiGene Foundation partnered with the health equity non-profit Max Foundation in 2023 to make Brukinsa available for free to patients in 29 countries over the following three years.